A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS.
Hudis C, et al. Among authors: chandarlapaty s.
Breast Cancer Res. 2013 Nov 19;15(6):R110. doi: 10.1186/bcr3577.
Breast Cancer Res. 2013.
PMID: 24252402
Free PMC article.
Clinical Trial.